Medimmune Limited

Astrazeneca Ab

Lorin Roskos

Brandon Higgs

Bing Wang

Meina Liang

David Fairman

Raffaella Faggioni

Marlon Rebelatto

Paul Robbins

Rajesh Narwal

Carlos Chavez

Christine K Ward

Amy Schneider

Donald Raible

Shengyan Hong

Li Shi

Anmarie Boutrin

Keith Steele

Hong Lu

Min Pak

Carina Herl

Li Yu

Mohammed Dar

Harry Yang

Charles Ferte

Ikbel Achour

Jolyon Faria

Jean-Charles Soria

Wei Zhao

Yihong Yao

Nestor Molfino

Pralay Mukhopadhyay

Aline Gendrin Brokmann

Joachim Almquist

Dominic Sinibaldi

Wendy White

Rajendra Tummala

Thomas Rouse

Yen Lin Chia

Catharina Lindholm

Linda Chang

Teodora Trasieva

Madhu Ramaswamy

Paul Newcombe

Tomas Rouse

Chris Kell

Richard May

Methods for determining treatments for cancer patients are disclosed.

Methods for determining treatment for cancer patients

The disclosure relates to methods and compositions for the treatment of type I IFN mediated disease. Specifically, the disclosure relates to a subcutaneous dose of a type I IFN receptor inhibitor.

Method of treating type 1 interferon (IFN)-mediated disease using a subcutaneous dosing regimen comprising anifrolumab

Provided herein are methods of treating B7-H1-expressing tumors comprising administering an effective amount of MEDI4736 or an antigen-binding fragment thereof.

Anti-B7-H1 antibodies for treating tumors

The disclosure provides methods for treating a subject having a type I IFN-mediated disease or disorder comprising administration of a fixed does of an anti-interferon alpha receptor antibody. The disclosure also provides methods for suppressing a type I interferon (IFN) gene signature (GS) in a subject. In addition, the disclosure provides methods of prognosing or monitoring disease progression in a subject having a type I IFN-mediated disease or disorder, methods of predicting a dosage regimen, methods of identifying a candidate therapeutic agent, methods of identifying a patient as a candidate for a therapeutic agent, and methods of designating a personalized therapy.

Fixed dosage regimens for anti-type I interferon receptor (IFNAR) antibodies

Provided herein are methods of improving asthma symptoms, e.g., as measured by an asthma control questionnaire, comprising administering to the patient an effective amount of benralizumab or an antigen-binding fragment thereof.

Methods for improving asthma symptoms using benralizumab

Provided herein is are methods of increasing forced expiratory volume in one second (FEV) in an asthma patient, comprising administering to the patient an effective amount of benralizumab or an antigen-binding fragment thereof.

Methods for increasing forced expiratory volume in asthmatics using benralizumab

Provided herein is are methods of reducing exacerbations of asthma in an asthma patient, comprising administering to the patient an effective amount of the anti-interleukin-5 receptor (IL-5R) antibody benralizumab or an antigen-binding fragment thereof.

Methods for reducing exacerbation rates of asthma using benralizumab

Growing community of inventors

Gaithersburg, MD, United States of America

Lorin Roskos